Advertisement
Aggregating prostate cancer data improves clinical care
Molecular-based assays aid diagnosis and treatment decisions
Genomic testing isn’t just for low-risk tumors
Inhibition could lead to treatments
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Research seeks to disrupt disease progression
Quest for selective androgen ablation in prostate cancer heats up
Robotic radical perineal prostatectomy has potential advantages
Recipient of a Prostate Cancer Foundation Special Challenge Award
Outcomes are no worse than curative therapy over follow-up as long as 6 years
Surprisingly, no, study finds
Advertisement
Advertisement